Using a CDAHFD-fed mouse model to rapidly develop MASH with progressive liver fibrosis [29, 30], we have shown that hepatic MCU knockdown robustly mitigated multiple aspects of the disease, including steatosis, inflammation, and fibrosis, as well as improved hepatic oxidative stress and mitochondrial dysfunction. This evidence concerns the gene MCU and steatosis.